State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Department of Liver and Infectious Diseases, No. 302 Hospital of Chinese People's Liberation Army, Beijing, China.
Gut. 2018 Dec;67(12):2181-2191. doi: 10.1136/gutjnl-2017-314641. Epub 2017 Sep 19.
The definition of acute-on-chronic liver failure (ACLF) based on cirrhosis, irrespective of aetiology, remains controversial. This study aimed to clarify the clinicopathological characteristics of patients with hepatitis B virus-related ACLF (HBV-ACLF) in a prospective study and develop new diagnostic criteria and a prognostic score for such patients.
The clinical data from 1322 hospitalised patients with acute decompensation of cirrhosis or severe liver injury due to chronic hepatitis B (CHB) at 13 liver centres in China were used to develop new diagnostic and prognostic criteria.
Of the patients assessed using the Chronic Liver Failure Consortium criteria with the exception of cirrhosis, 391 patients with ACLF were identified: 92 with non-cirrhotic HBV-ACLF, 271 with cirrhotic HBV-ACLF and 28 with ACLF with cirrhosis caused by non-HBV aetiologies (non-HBV-ACLF). The short-term (28/90 days) mortality of the patients with HBV-ACLF were significantly higher than those of the patients with non-HBV-ACLF. Total bilirubin (TB) ≥12 mg/dL and an international normalised ratio (INR) ≥1.5 was proposed as an additional diagnostic indicator of HBV-ACLF, and 19.3% of patients with an HBV aetiology were additionally diagnosed with ACLF. The new prognostic score (0.741×INR+0.523×HBV-SOFA+0.026×age+0.003×TB) for short-term mortality was superior to five other scores based on both discovery and external validation studies.
Regardless of the presence of cirrhosis, patients with CHB, TB ≥12 mg/dL and INR ≥1.5 should be diagnosed with ACLF. The new criteria diagnosed nearly 20% more patients with an HBV aetiology with ACLF, thus increasing their opportunity to receive timely intensive management.
基于肝硬化定义急性慢性肝衰竭(ACLF),无论病因如何,仍存在争议。本研究旨在通过前瞻性研究明确乙型肝炎病毒相关 ACLF(HBV-ACLF)患者的临床病理特征,并为这类患者开发新的诊断标准和预后评分。
来自中国 13 家肝脏中心的 1322 例因慢性乙型肝炎(CHB)急性失代偿或严重肝损伤住院患者的临床数据,用于开发新的诊断和预后标准。
采用除肝硬化以外的慢性肝衰竭联盟标准评估患者时,发现 391 例 ACLF 患者:92 例非肝硬化 HBV-ACLF,271 例肝硬化 HBV-ACLF 和 28 例由非乙型肝炎病因引起的 ACLF(非 HBV-ACLF)。HBV-ACLF 患者的短期(28/90 天)死亡率明显高于非 HBV-ACLF 患者。总胆红素(TB)≥12mg/dL 和国际标准化比值(INR)≥1.5 被提议作为 HBV-ACLF 的附加诊断指标,HBV 病因的 19.3%的患者被额外诊断为 ACLF。新的短期死亡率预后评分(0.741×INR+0.523×HBV-SOFA+0.026×年龄+0.003×TB)优于基于发现和外部验证研究的其他 5 种评分。
无论是否存在肝硬化,TB≥12mg/dL 和 INR≥1.5 的 CHB 患者均应诊断为 ACLF。新标准诊断出近 20%的乙型肝炎病因 ACLF 患者,从而增加了他们获得及时强化治疗的机会。